APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Genetic Testing For Neurological Disorders

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Genetic Testing For Neurological Disorders Market Outlook and Growth Opportunities 2026

Report ID 174149040428 December 2025197 pages

Choose your research edition.

Industry ResearchGenetic Testing For Neurological Disorders Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Testing For Neurological Disorders Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Genetic Testing For Neurological Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Testing For Neurological Disorders Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Testing For Neurological Disorders Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Genetic Testing For Neurological Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Genetic Testing For Neurological Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genetic Testing For Neurological Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetic Testing For Neurological Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Genetic Testing For Neurological Disorders market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Genetic Testing For Neurological Disorders market include Illumina, CENTOGENE, Victorian Clinical Genetics Services, PacBio, Mayo Clinic, Quest Diagnostics, MedGenome Labs, GeneDx and Connecticut Children's, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Genetic Testing For Neurological Disorders market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genetic Testing For Neurological Disorders and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genetic Testing For Neurological Disorders revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Genetic Testing For Neurological Disorders market.

Genetic Testing For Neurological Disorders Segment by Company

Illumina

CENTOGENE

Victorian Clinical Genetics Services

PacBio

Mayo Clinic

Quest Diagnostics

MedGenome Labs

GeneDx

Connecticut Children's

Labcorp (Invitae/MNG Laboratories)

Genetic Testing For Neurological Disorders Segment by Type

Exome Sequencing

Whole Genome Sequencing

RNA Sequencing

General DNA Testing

Genetic Testing For Neurological Disorders Segment by Application

Hospitals

Specialty Clinics

Diagnostics Laboratories

Genetic Testing For Neurological Disorders Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Genetic Testing For Neurological Disorders status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Genetic Testing For Neurological Disorders key companies, revenue, market share, and recent developments.

3. To split the Genetic Testing For Neurological Disorders breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Genetic Testing For Neurological Disorders market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Genetic Testing For Neurological Disorders significant trends, drivers, influence factors in global and regions.

6. To analyze Genetic Testing For Neurological Disorders competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Testing For Neurological Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Testing For Neurological Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Testing For Neurological Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Genetic Testing For Neurological Disorders industry.

Chapter 3: Detailed analysis of Genetic Testing For Neurological Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Genetic Testing For Neurological Disorders in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Genetic Testing For Neurological Disorders in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Genetic Testing For Neurological Disorders Industry Trends Table 2. Genetic Testing For Neurological Disorders Industry Drivers Table 3. Genetic Testing For Neurological Disorders Industry Opportunities and Challenges Table 4. Genetic Testing For Neurological Disorders Industry Restraints Table 5. Global Genetic Testing For Neurological Disorders Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Genetic Testing For Neurological Disorders Revenue Share by Company (2021-2026) Table 7. Global Genetic Testing For Neurological Disorders Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Genetic Testing For Neurological Disorders Key Company Manufacturing Base & Headquarters Table 9. Global Genetic Testing For Neurological Disorders Company, Product Type & Application Table 10. Global Genetic Testing For Neurological Disorders Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Genetic Testing For Neurological Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Exome Sequencing Table 15. Significant Companies of Whole Genome Sequencing Table 16. Significant Companies of RNA Sequencing Table 17. Significant Companies of General DNA Testing Table 18. Global Genetic Testing For Neurological Disorders Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Genetic Testing For Neurological Disorders Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Genetic Testing For Neurological Disorders Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Genetic Testing For Neurological Disorders Sales Value Share by Type (2021-2026) Table 22. Global Genetic Testing For Neurological Disorders Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Specialty Clinics Table 25. Significant Companies of Diagnostics Laboratories Table 26. Global Genetic Testing For Neurological Disorders Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Genetic Testing For Neurological Disorders Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Genetic Testing For Neurological Disorders Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Genetic Testing For Neurological Disorders Sales Value Share by Application (2021-2026) Table 30. Global Genetic Testing For Neurological Disorders Sales Value Share by Application (2027-2032) Table 31. Global Genetic Testing For Neurological Disorders Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Genetic Testing For Neurological Disorders Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Genetic Testing For Neurological Disorders Sales Value Share by Region (2021-2026) Table 34. Global Genetic Testing For Neurological Disorders Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Genetic Testing For Neurological Disorders Sales Value Share by Region (2027-2032) Table 36. Global Genetic Testing For Neurological Disorders Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Genetic Testing For Neurological Disorders Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Genetic Testing For Neurological Disorders Sales Value Market Share by Country (2021-2026) Table 39. Global Genetic Testing For Neurological Disorders Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Genetic Testing For Neurological Disorders Sales Value Market Share by Country (2027-2032) Table 41. Illumina Company Information Table 42. Illumina Business Overview Table 43. Illumina Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Illumina Genetic Testing For Neurological Disorders Product Portfolio Table 45. Illumina Recent Development Table 46. CENTOGENE Company Information Table 47. CENTOGENE Business Overview Table 48. CENTOGENE Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. CENTOGENE Genetic Testing For Neurological Disorders Product Portfolio Table 50. CENTOGENE Recent Development Table 51. Victorian Clinical Genetics Services Company Information Table 52. Victorian Clinical Genetics Services Business Overview Table 53. Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Product Portfolio Table 55. Victorian Clinical Genetics Services Recent Development Table 56. PacBio Company Information Table 57. PacBio Business Overview Table 58. PacBio Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. PacBio Genetic Testing For Neurological Disorders Product Portfolio Table 60. PacBio Recent Development Table 61. Mayo Clinic Company Information Table 62. Mayo Clinic Business Overview Table 63. Mayo Clinic Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Mayo Clinic Genetic Testing For Neurological Disorders Product Portfolio Table 65. Mayo Clinic Recent Development Table 66. Quest Diagnostics Company Information Table 67. Quest Diagnostics Business Overview Table 68. Quest Diagnostics Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Quest Diagnostics Genetic Testing For Neurological Disorders Product Portfolio Table 70. Quest Diagnostics Recent Development Table 71. MedGenome Labs Company Information Table 72. MedGenome Labs Business Overview Table 73. MedGenome Labs Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. MedGenome Labs Genetic Testing For Neurological Disorders Product Portfolio Table 75. MedGenome Labs Recent Development Table 76. GeneDx Company Information Table 77. GeneDx Business Overview Table 78. GeneDx Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. GeneDx Genetic Testing For Neurological Disorders Product Portfolio Table 80. GeneDx Recent Development Table 81. Connecticut Children's Company Information Table 82. Connecticut Children's Business Overview Table 83. Connecticut Children's Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Connecticut Children's Genetic Testing For Neurological Disorders Product Portfolio Table 85. Connecticut Children's Recent Development Table 86. Labcorp (Invitae/MNG Laboratories) Company Information Table 87. Labcorp (Invitae/MNG Laboratories) Business Overview Table 88. Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Product Portfolio Table 90. Labcorp (Invitae/MNG Laboratories) Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Genetic Testing For Neurological Disorders Product Image Figure 2. Global Genetic Testing For Neurological Disorders Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Testing For Neurological Disorders Market Size (2021-2032) & (US$ Million) Figure 4. Global Genetic Testing For Neurological Disorders Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Exome Sequencing Image Figure 8. Whole Genome Sequencing Image Figure 9. RNA Sequencing Image Figure 10. General DNA Testing Image Figure 11. Global Genetic Testing For Neurological Disorders Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Genetic Testing For Neurological Disorders Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Genetic Testing For Neurological Disorders Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. Specialty Clinics Image Figure 16. Diagnostics Laboratories Image Figure 17. Global Genetic Testing For Neurological Disorders Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Genetic Testing For Neurological Disorders Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Genetic Testing For Neurological Disorders Sales Value Share by Application (2021-2032) Figure 20. Global Genetic Testing For Neurological Disorders Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Genetic Testing For Neurological Disorders Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Genetic Testing For Neurological Disorders Sales Value (2021-2032) & (US$ Million) Figure 23. North America Genetic Testing For Neurological Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Genetic Testing For Neurological Disorders Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Genetic Testing For Neurological Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Genetic Testing For Neurological Disorders Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Genetic Testing For Neurological Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Genetic Testing For Neurological Disorders Sales Value (2021-2032) & (US$ Million) Figure 29. South America Genetic Testing For Neurological Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Genetic Testing For Neurological Disorders Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Genetic Testing For Neurological Disorders Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Exome Sequencing
  • Whole Genome Sequencing
  • RNA Sequencing
  • General DNA Testing
Applications
  • Hospitals
  • Specialty Clinics
  • Diagnostics Laboratories
Companies covered
  • Illumina
  • CENTOGENE
  • Victorian Clinical Genetics Services
  • PacBio
  • Mayo Clinic
  • Quest Diagnostics
  • MedGenome Labs
  • GeneDx
  • Connecticut Children's
  • Labcorp (Invitae/MNG Laboratories)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Genetic Testing For Neurological Disorders Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Genetic Testing For Neurological Disorders Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Genetic Testing For Neurological Disorders Market Dynamics
  1. 2.1 Genetic Testing For Neurological Disorders Industry Trends
  2. 2.2 Genetic Testing For Neurological Disorders Industry Drivers
  3. 2.3 Genetic Testing For Neurological Disorders Industry Opportunities and Challenges
  4. 2.4 Genetic Testing For Neurological Disorders Industry Restraints
3 Genetic Testing For Neurological Disorders Market by Company
  1. 3.1 Global Genetic Testing For Neurological Disorders Company Revenue Ranking in 2025
  2. 3.2 Global Genetic Testing For Neurological Disorders Revenue by Company (2021-2026)
  3. 3.3 Global Genetic Testing For Neurological Disorders Company Ranking (2024-2026)
  4. 3.4 Global Genetic Testing For Neurological Disorders Company Manufacturing Base and Headquarters
  5. 3.5 Global Genetic Testing For Neurological Disorders Company Product Type and Application
  6. 3.6 Global Genetic Testing For Neurological Disorders Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Genetic Testing For Neurological Disorders Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Genetic Testing For Neurological Disorders Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Genetic Testing For Neurological Disorders Market by Type
  1. 4.1 Genetic Testing For Neurological Disorders Type Introduction
  2. 4.1.1 Exome Sequencing
  3. 4.1.2 Whole Genome Sequencing
  4. 4.1.3 RNA Sequencing
  5. 4.1.4 General DNA Testing
  6. 4.2 Global Genetic Testing For Neurological Disorders Sales Value by Type
  7. 4.2.1 Global Genetic Testing For Neurological Disorders Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Genetic Testing For Neurological Disorders Sales Value by Type (2021-2032)
  9. 4.2.3 Global Genetic Testing For Neurological Disorders Sales Value Share by Type (2021-2032)
5 Genetic Testing For Neurological Disorders Market by Application
  1. 5.1 Genetic Testing For Neurological Disorders Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Specialty Clinics
  4. 5.1.3 Diagnostics Laboratories
  5. 5.2 Global Genetic Testing For Neurological Disorders Sales Value by Application
  6. 5.2.1 Global Genetic Testing For Neurological Disorders Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Genetic Testing For Neurological Disorders Sales Value by Application (2021-2032)
  8. 5.2.3 Global Genetic Testing For Neurological Disorders Sales Value Share by Application (2021-2032)
6 Genetic Testing For Neurological Disorders Regional Value Analysis
  1. 6.1 Global Genetic Testing For Neurological Disorders Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genetic Testing For Neurological Disorders Sales Value by Region (2021-2032)
  3. 6.2.1 Global Genetic Testing For Neurological Disorders Sales Value by Region: 2021-2026
  4. 6.2.2 Global Genetic Testing For Neurological Disorders Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Genetic Testing For Neurological Disorders Sales Value (2021-2032)
  7. 6.3.2 North America Genetic Testing For Neurological Disorders Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Genetic Testing For Neurological Disorders Sales Value (2021-2032)
  10. 6.4.2 Europe Genetic Testing For Neurological Disorders Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Genetic Testing For Neurological Disorders Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Genetic Testing For Neurological Disorders Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Genetic Testing For Neurological Disorders Sales Value (2021-2032)
  16. 6.6.2 South America Genetic Testing For Neurological Disorders Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Genetic Testing For Neurological Disorders Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Genetic Testing For Neurological Disorders Sales Value Share by Country, 2025 VS 2032
7 Genetic Testing For Neurological Disorders Country-level Value Analysis
  1. 7.1 Global Genetic Testing For Neurological Disorders Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Genetic Testing For Neurological Disorders Sales Value by Country (2021-2032)
  3. 7.2.1 Global Genetic Testing For Neurological Disorders Sales Value by Country (2021-2026)
  4. 7.2.2 Global Genetic Testing For Neurological Disorders Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Genetic Testing For Neurological Disorders Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Genetic Testing For Neurological Disorders Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Genetic Testing For Neurological Disorders Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Illumina
  2. 8.1.1 Illumina Company Information
  3. 8.1.2 Illumina Business Overview
  4. 8.1.3 Illumina Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Illumina Genetic Testing For Neurological Disorders Product Portfolio
  6. 8.1.5 Illumina Recent Developments
  7. 8.2 CENTOGENE
  8. 8.2.1 CENTOGENE Company Information
  9. 8.2.2 CENTOGENE Business Overview
  10. 8.2.3 CENTOGENE Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CENTOGENE Genetic Testing For Neurological Disorders Product Portfolio
  12. 8.2.5 CENTOGENE Recent Developments
  13. 8.3 Victorian Clinical Genetics Services
  14. 8.3.1 Victorian Clinical Genetics Services Company Information
  15. 8.3.2 Victorian Clinical Genetics Services Business Overview
  16. 8.3.3 Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Product Portfolio
  18. 8.3.5 Victorian Clinical Genetics Services Recent Developments
  19. 8.4 PacBio
  20. 8.4.1 PacBio Company Information
  21. 8.4.2 PacBio Business Overview
  22. 8.4.3 PacBio Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PacBio Genetic Testing For Neurological Disorders Product Portfolio
  24. 8.4.5 PacBio Recent Developments
  25. 8.5 Mayo Clinic
  26. 8.5.1 Mayo Clinic Company Information
  27. 8.5.2 Mayo Clinic Business Overview
  28. 8.5.3 Mayo Clinic Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mayo Clinic Genetic Testing For Neurological Disorders Product Portfolio
  30. 8.5.5 Mayo Clinic Recent Developments
  31. 8.6 Quest Diagnostics
  32. 8.6.1 Quest Diagnostics Company Information
  33. 8.6.2 Quest Diagnostics Business Overview
  34. 8.6.3 Quest Diagnostics Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Quest Diagnostics Genetic Testing For Neurological Disorders Product Portfolio
  36. 8.6.5 Quest Diagnostics Recent Developments
  37. 8.7 MedGenome Labs
  38. 8.7.1 MedGenome Labs Company Information
  39. 8.7.2 MedGenome Labs Business Overview
  40. 8.7.3 MedGenome Labs Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MedGenome Labs Genetic Testing For Neurological Disorders Product Portfolio
  42. 8.7.5 MedGenome Labs Recent Developments
  43. 8.8 GeneDx
  44. 8.8.1 GeneDx Company Information
  45. 8.8.2 GeneDx Business Overview
  46. 8.8.3 GeneDx Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GeneDx Genetic Testing For Neurological Disorders Product Portfolio
  48. 8.8.5 GeneDx Recent Developments
  49. 8.9 Connecticut Children's
  50. 8.9.1 Connecticut Children's Company Information
  51. 8.9.2 Connecticut Children's Business Overview
  52. 8.9.3 Connecticut Children's Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Connecticut Children's Genetic Testing For Neurological Disorders Product Portfolio
  54. 8.9.5 Connecticut Children's Recent Developments
  55. 8.10 Labcorp (Invitae/MNG Laboratories)
  56. 8.10.1 Labcorp (Invitae/MNG Laboratories) Company Information
  57. 8.10.2 Labcorp (Invitae/MNG Laboratories) Business Overview
  58. 8.10.3 Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Product Portfolio
  60. 8.10.5 Labcorp (Invitae/MNG Laboratories) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst